Immuneering Corporation
IMRXHealthcareNASDAQBiotechnology · Last scanned Jun 3, 2026
Scan Results
Daily timeframeImmuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. At a $276.9M market cap, Immuneering Corporation ranks as a micro-cap company within healthcare. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs.
Market Cap
$276.9M
Beta
0.36
P/E (TTM)
—
P/E (Fwd)
-3.20
EPS (TTM)
$-1.06
EPS (Fwd)
$-1.34
ROE
-43.8%
ROA
-27.9%
Cash
$156.7M
Total Debt
$3.7M
Free CF
-$33.2M
52W Change
118.4%
Annual Financials
Cash vs Debt
With $156.7M in cash and $3.7M in debt, IMRX maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$33.2M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -43.8%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $317K (2022) to $0 (2025), a 100% decline worth watching.
With a beta below 0.7, Immuneering Corporation typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. With cash comfortably exceeding debt, IMRX has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Immuneering Corporation and its sector.